Close Menu

Sygnis

The deal includes Expedeon's core proteomics business, as well as its immunology-focused subsidiaries Innova Biosciences and TGR Biosciences.

The revenue growth was driven in part by sales generated by Australian reagent maker TGR Biosciences, which Expedeon acquired in May last year.

The German research products firm attributed the higher revenues to organic growth, as well as the impact of recent acquisitions such as TGR Biosciences.

The firm will use the agreement to access alternative non-dilutive means of financing of its growth plans.

The company, which has just changed its name from Sygnis, has now completed the integration of several recent acquisitions including TGR Biosciences.

The company anticipates 2018 revenues in the range of €11 million to €12 million, excluding the impact of recently acquired TGR Biosciences.

TGR's proprietary protein capturing technology is expected to complement Sygnis' range of immunology, genomic, and proteomic products and services.

The company had intended to raise up to €6.6 million through the placement to help fund its planned acquisition of TGR Biosciences.

Sygnis said that TGR is profitable and has a complementary product portfolio that includes protein capture technology.

This week's news includes Danaher, BGI, Mobadiag, and Sygnis.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.